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Background: Women with pregnancy complicated by pregestational diabetes experience increased rates of adverse
pregnancy outcomes. Prepregnancy care is the targeted support and additional care offered to those women who
are planning pregnancy and is associated with improved outcomes. However, there is significant heterogeneity in the
outcomes measured and reported in studies evaluating the effects of prepregnancy care, which makes meaningful
comparison difficult. The aim of this article is to present a protocol for a study to develop a Core Outcome Set (COS)
for trials and other studies evaluating the effectiveness of prepregnancy care for women with pregestational diabetes
mellitus.
Methods/Design: This study will include a systematic review of the literature to identify outcomes that have previously
been reported in studies evaluating prepregnancy care for women with pregestational diabetes. We will then prioritise
these outcomes from the perspective of key stakeholders, including women with pregestational diabetes as well as
clinicians, using a Delphi survey. A final consensus meeting will be held with stakeholders to review and finalise the
outcomes.
Discussion: The expectation is that the COS will always be collected and reported in all clinical trials, audits of practice
and other forms of research that involve prepregnancy care programs for women with pregestational diabetes. This will
facilitate comparing and contrasting of studies and allow for combining of appropriate studies with the ultimate goal of
improved patient care.
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diabetesBackground
Despite modern approaches to diabetes care, pregnancy
can pose significant risk to both mother and infant in
the presence of type 1 or type 2 diabetes, also described
as pregestational diabetes [1]. Women with pregnancy
complicated by diabetes have increased rates of adverse
pregnancy outcomes, including a congenital malformation* Correspondence: aoife.egan@gmail.com
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article, unless otherwise stated.rate twice that of the general maternity population, a five-
fold increased risk of stillbirth and a threefold increased
risk of perinatal mortality [2, 3]. The caesarean section
rate for women with diabetes in pregnancy is 67 %, as
compared with 22 % in the background population. The
rate of macrosomia among with diabetes in pregnancy is
approximately 21 %, as compared with 11 % in the general
maternity population [2–5].
The provision of structured clinical care before preg-
nancy, however, is associated with improved outcomes
[6, 7]. This is particularly true for rates of malformationsis distributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
give appropriate credit to the original author(s) and the source, provide a
indicate if changes were made. The Creative Commons Public Domain
.org/publicdomain/zero/1.0/) applies to the data made available in this
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extent to poor glycaemic control earlier rather than later
in pregnancy [8]. The mechanism of this relationship is
clear when one considers that foetal organogenesis is
essentially completed by 7 weeks of gestation, often
before the woman knows she is pregnant [9]. It is recom-
mended, therefore, that all women of reproductive age
with diabetes be offered annual preconception counselling
and advised to avoid unplanned pregnancy [6, 10]. Pre-
pregnancy care is the targeted support, and additional care
is offered to women who are actually planning pregnancy
[6]. Once women are ready to engage with prepregnancy
care, they are reviewed at intervals of 1–3 months by a
multidisciplinary team. This team typically includes a dia-
betes physician, a diabetes nurse and/or midwife specialist
and a dietician. Women will undergo a full medication
review, a review of diabetes-related complications, an as-
sessment for other conditions more commonly associated
with diabetes (e.g., thyroid and coeliac disease) and com-
mence folic acid therapy. Diabetes-related complications
and thyroid status will be assessed, and glycaemic
control will be optimized. It is recommended that the
glycosylated haemoglobin A1c (HbA1c) level should be
below 48 mmol/mol (6.5 %) if achievable without caus-
ing problematic hypoglycaemia [10]. There is not, how-
ever, an agreed standardised approach for provision of
this care, and, though many groups have reported posi-
tive benefits associated with their own prepregnancy
programs, outcomes reported are varied and diverse
[6, 7, 11].
Development of a core outcome set
Clinical studies should have defined outcomes that an-
swer questions generated by the main hypothesis [12].
The outcomes potentially relevant to prepregnancy care
programs are diverse and include both maternal and
foetal outcomes. Unfortunately, there is significant het-
erogeneity in the outcomes measured and reported in
studies evaluating the effects of prepregnancy care for
women with pregestational diabetes. This is highlighted
in a systematic review and meta-analysis by Wahabi
et al., who noted that, of 21 included studies, only 13
included congenital malformations as an outcome of
prepregnancy care and only 5 included the difference in
the level of HbA1c [13]. This inconsistency in outcomes
between studies makes meaningful comparison difficult
and limits the ability to combine individual studies’ find-
ings into summarised estimates. Further concerns
include non-uniform outcome selection and reporting
bias in clinical studies. These issues involve researchers’
selecting outcomes that suit their needs and reporting
only favourable results [14, 15]. To further highlight this
issue, a recent descriptive survey of 6127 outcomes in
788 Cochrane reviews found that 37 % of prespecifiedoutcomes were not actually reported [16]. If study find-
ings are to influence policy and practice, then the chosen
outcomes need to be relevant and important to key
stakeholders to facilitate development of high-quality
care [15]. The authors of a recent Cochrane review [17]
could identify only one randomised controlled trial
evaluating different models of prepregnancy care for
women with diabetes [18]. They recommended strongly
the need for further, large, high-quality randomised con-
trolled trials to evaluate the effect of different protocols
of preconception care for women with preexisting dia-
betes [17]. There is a risk that, owing to lack of guidance
on appropriate outcomes, the usefulness of this future
research in informing clinical practice will be limited.
One method of addressing this lack of uniformity is
through the development, use and reporting of an
agreed set of outcomes, known as a Core Outcome Set
(COS). The expectation is that the COS will always be
collected and reported in all clinical trials, audits of
practice and other forms of research that involve a spe-
cific clinical condition [15]. This will facilitate comparing
and contrasting of studies and allow for combining of
appropriate studies. The development of such COS is fa-
cilitated and supported by the Core Outcome Measures
in Effectiveness Trials Initiative, which was launched in
2010 and brings together interested researchers while
minimising duplication of effort [15, 19]. Importantly, a
COS does not restrict researchers from evaluating add-
itional outcomes; rather, it represents a minimum that
should be collected and reported. COS are now devel-
oped for many aspects of patient care. In 2014, the
editors of over 50 journals began the Core Outcomes in
Women’s Health Initiative [20–23]. This initiative has a
number of aims, which include encouraging researchers
to develop COS in the field of women’s health, organising
robust peer review and facilitating effective dissemination
of manuscripts [20].
Study aim
The aim of this article is to present a protocol for a
study to develop COS for trials and other studies evalu-
ating the effectiveness of prepregnancy care for women
with pregestational diabetes mellitus.
Study objectives
Our objective is to describe in detail the following steps
necessary to develop the COS:
1. Complete a systematic literature review to identify
outcomes reported in studies evaluating
prepregnancy care for women with pregestational
diabetes
2. Prioritise these outcomes from the perspective of
key stakeholders, including women with
Egan et al. Trials  (2015) 16:356 Page 3 of 7pregestational diabetes and clinicians, using a Delphi
survey and consensus meeting
Methods/Design
Ethics
Ethical approval to conduct this study was sought and
obtained from the ethics committee at Galway University
Hospitals (home institution of the study’s principal
investigator).
Part 1: Generation of a list containing possible relevant
outcomes
Systematic review question
What are the outcomes reported in studies assessing the
effectiveness of prepregnancy care for women with preg-
estational diabetes?
Methods
Using a comprehensive search strategy, the following da-
tabases will be searched for relevant studies: MEDLINE),
Embase, Web of Science, Cochrane Library and CINAHL.
ClinicalTrials.gov will also be searched for relevant,
ongoing trials. Key terms used to guide the search will in-
clude ‘diabetes’, ‘pregnancy’, ‘prepregnancy’, ‘pre-pregnancy’,
‘preconception’ and ‘preconception’, combined as ap-
propriate using the Boolean operands ‘AND’ and ‘OR’.
Additional file 1 outlines the detailed search strategies
and time limits applied to each of the databases. The
reference lists of all relevant studies will be searched
for additional relevant studies not retrieved from the
electronic database search. Language restrictions will
not be applied to the search strategy; however, selection
of relevant articles will be restricted to English-
language publications. Searching all languages will
enable us to identify the extent of potentially eligible
additional studies that will not be included and con-
sider if this presents a source of language bias.
Types of studies
For the purpose of this phase of the development of the
COS, we will include prospective cohort studies, case–
control trials, randomised trials and systematic reviews
(with and without meta-analyses) comparing women
who did and did not receive prepregnancy care. In line
with prior work in this area, we will exclude review
reports and reports of conference proceedings or ab-
stracts when there is no complete description of the trial
or study [13].
Types of interventions
We will use a definition of prepregnancy care similar to
that of Wahabi and colleagues [13]. This includes the
following as a sole intervention or in combination for
women with type 1 and/or type 2 diabetes:1. Glycaemic control by insulin, oral pharmacologic
agents and/or diet, aiming at fasting blood glucose
≤5.7 mmol/L and/or postprandial blood glucose
≤7.8 mmol/L and/or HbA1c ≤7.0 %
2. Counselling and/or education about diabetes
complications during pregnancy, the importance of
glycaemic control and self-monitoring of blood
glucose level
3. Prepregnancy screening and treatment of
complications of diabetes (e.g., retinopathy,
nephropathy, hypertension)
4. The use of contraception until optimization of
glycaemic control is achieved
5. Vitamin or folic acid supplementation in the
prepregnancy period
Types of participants
Participants will be women of reproductive age with
pregestational diabetes mellitus who were not pregnant
at the time of intervention.
Study assessment
An initial selection of studies identified in the search will
be performed using the predetermined review inclusion
criteria. Two reviewers (FPD and AME) will independ-
ently assess the titles and abstracts of selected studies.
Full texts of studies meeting the inclusion criteria, or
where there is uncertainty regarding inclusion at title
and abstract screening, will be retrieved and reviewed
with final decisions on inclusion or exclusion achieved
through consensus. In cases of disagreement, a third in-
dependent reviewer (VS) will be consulted.
Data extraction
The following data will be extracted from each study:
study design, author details, year and journal of publica-
tion, targeted condition (i.e., type 1 or type 2 diabetes or
both), interventions under investigation, each effective-
ness outcome specified in Methods section and/or find-
ings, whether the outcome was defined or not, the
definition used, the indicators and/or tools used to
measure the outcomes and the time points or periods of
outcome measurement. Two review authors (AME and
FPD) will extract data independently, review the data to-
gether, assess consensus and ensure that all outcomes
have been identified. Disagreement will be resolved
through discussion. Where a resolution is not possible, a
third reviewer (VS) will be consulted.
Data analysis and presentation
Data will be tabulated so that each study is listed and all
outcomes measured in each study are displayed separ-
ately. Following this, outcomes will be further grouped
under domains (e.g., maternal outcomes and neonatal
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FPD and DD. The number of outcomes used to reflect
each domain and the number of different definitions and
methods of measurements used will be described.
Part 2: Developing a consensus on outcomes important
to different stakeholders using a Delphi survey and
consensus meeting
Delphi survey
Methods To develop consensus on outcomes of import-
ance to key stakeholders for inclusion in the COS, a
Delphi method will be adopted. This method is iterative
and uses a series of rounds of data collection and ana-
lysis to condense the opinions of individuals into a
group consensus. Typically, it involves the use of se-
quential rounds of questionnaires designed to elicit par-
ticipants’ opinions on a particular topic. Responses to
each round are collated, analysed and redistributed to
participants for further comment in successive rounds
[21]. This technique has advantages over less structured
methods of reaching consensus, such as roundtable dis-
cussions. It avoids a situation where certain individuals
can dominate a discussion or where other individuals
feel obliged to agree with the opinions of more senior
members [24]. It also facilitates wide international par-
ticipation and increased numbers of stakeholders
informing the prioritisation process. To improve effi-
ciency, the questionnaire will be completed online using
QuestionPro software (http://www.questionpro.com/) or
similar such software appropriate to online survey
design.
The list of potential outcomes finalised in part 1 will
be formatted into a list of outcomes with a response de-
signed to allow the participants to rate each one of the
outcomes on a 9-point Likert-type scale, with higher
values representing increased importance for inclusion
of the outcome in the COS. Following review of the out-
come list by the research group (AME, VS, DD and
FPD), the list will be circulated to the study advisory
group (SAG). The SAG, composed of key stakeholders,
will be asked to comment on the overall list of outcomes
and the suitability of the domains under which they are
grouped. They will additionally be asked to list any other
outcomes that they think should be included. These
other outcomes will be added to the list for inclusion in
the Delphi survey. Members of the SAG will not partici-
pate in the Delphi exercise, as they had a role in study
design, which may influence scoring. Instead, they will
be invited to participate in the final consensus meeting.
Participants
The key stakeholders include women, clinicians and re-
searchers. Women, who represent service users, will have
a known diagnosis of type 1 or type 2 diabetes mellitus orrepresent women with such diagnoses. Recruitment will
include listed groups of diabetes services users (e.g.,
Diabetes Ireland) accessed via the electronic discussion
email list manager. The manager will be emailed informa-
tion on the survey and a request to distribute an invitation
email to members on their email lists. The list managers
will have an opportunity to contact the researcher directly
to clarify any issues or to seek further information about
the survey and the research before making a decision. The
distribution of the survey will be at the discretion of the
email list manager. Clinical leads at participating hospitals
will also be asked to invite service users to participate via
their prepregnancy and diabetes care clinical teams.
Clinicians will include obstetricians, endocrinologists,
midwives, diabetes midwife and/or nurse specialists and
dieticians. Researchers with expertise in diabetes care will
be also invited to participate. Clinicians and researchers
will be invited from specialist centres globally. Clinical
leads will be identified and recruited through the Diabetes
in Pregnancy Study Group, which is a study group of the
European Association for the Study of Diabetes. These
clinical leads will be invited to participate by email and
will be asked to forward the study details to other
members of their prepregnancy care teams. Snowball sam-
pling will be used, whereby participants from all the above
groups will be asked to forward the invitation to others
whom they regard as having the required expertise. Al-
though there is no consensus on the ideal number of par-
ticipants for a Delphi survey, we will aim for a total of 180
participants, including at least 30 service users [21, 25].
Each participant will be emailed a letter of invitation out-
lining the study and the link to the online survey.
Informed consent to participate in the study will be
obtained from each participant upon registration for the
online Delphi questionnaire. The consent process will
occur before submission of any answers. The importance
of completing the whole Delphi survey process will be
emphasised, and generic reminder emails will be sent to
aid completion of each round. A unique identifier will be
assigned to each participant, tracked to their email
address, which will allow monitoring of attrition at each
round.Delphi study round 1
The online questionnaire will request the participant’s
name, email address and centre with which they are
aligned in either receiving (users) or providing and/or
researching on prepregnancy diabetes care (clinicians
and/or researchers). Participants will be asked to identify
the stakeholder group and subgroup to which they be-
long. They will be asked to complete the questionnaire
within 3 weeks and will be prompted after week 2 with
an email reminder. The questionnaires will contain lay
Table 1 Definitions of consensusa
Classification Definition
Consensus in ≥70 % participants scoring as 7–9 and <15 %
participants scoring as 1–3
Consensus out ≥70 % participants scoring as 1–3 and <15 %
participants scoring as 7–9
No consensus Anything else
aDeveloped according to the Management of Otitis Media with Effusion in
Cleft Palate protocol [12]
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understanding complex terminology.
The list of outcomes to be scored will be ordered
alphabetically to avoid weighting of outcomes caused by
the order in which they are displayed. There will be an
option for a participant to add up to two additional out-
comes and provide an associated score. They will be
asked the following key question: ‘Prepregnancy care for
women with pre-existing diabetes can have a variety of
beneficial effects, each of which could be measured as
an outcome in a clinical study. Please score how import-
ant each of the following outcomes is on a scale of 1–9’.
Scores will be grouped into 1–3 = not important, 4–6 = im-
portant but not critical or 7–9 = critical. This scale was
devised by the Grading of Recommendations Assessment,
Development and Evaluation and has been adopted in
other core outcome development research groups using
the Delphi method [12, 25].
Analysis of round 1
The results of round 1 will be summarised using
descriptive statistics, including the proportion of partici-
pants scoring for each rating point on the Likert scale
(i.e., for each point from 1 to 9). Any additional out-
comes listed will be reviewed by the researchers (AME
and FPD). If they are deemed to represent a new
outcome based on this review, they will be included for
round 2 and the SAG will be consulted to review if ap-
propriate. All outcomes will be carried forward to round
2. Of note, continuation to round 2 will be considered
based on the response to round 1. If a low number of
responders (<10) is observed for one or more stake-
holder groups, the Delphi protocol for future rounds will
be reviewed and revised. If there is only one stakeholder
group with a small number of respondents, then consid-
eration will be given to grouping with another stake-
holder group following consultation with the SAG to
ensure appropriateness of grouping.
Delphi study round 2
Participants who respond to round 1 will be forwarded
the round 2 questionnaire and asked to complete it
online. Each participant will be presented with the num-
ber of respondents and distribution of scores for each
outcome per stakeholder group. They will also be shown
their score from round 1, asked to consider responses
from the other members of the stakeholder groups and
invited to rescore the outcome.
Analysis of round 2
The results of round 2 will be summarised using de-
scriptive statistics. The number of participants taking
part will be recorded. For each outcome, the number of
participants who have scored the outcome and thedistribution of scores will be noted. All outcomes that
have a median score ≥4 for any group will be carried for-
ward to round 3. Participants who completed rounds 1
and 2 will be invited to complete round 3.
Delphi study round 3
Participants who respond to rounds 1 and 2 will be
forwarded the round 3 questionnaire and asked to
complete it online. Again, each participant will be pre-
sented with the number of respondents and distribu-
tion of scores for each outcome for their particular
stakeholder group. They will also be shown their score
from round 2, asked to consider responses of other
members of the stakeholder group and asked to re-
score the outcome.
Analysis of round 3
The results of round 3 will be summarised using de-
scriptive statistics. The number of participants taking
part will be recorded. For each outcome, the number of
participants who have scored the outcome and the dis-
tribution of scores will be noted. Each outcome will be
classified as ‘consensus in’, ‘consensus out’ or ‘no consen-
sus’ according to the classifications in Table 1. Although
these cutoffs are subjective, they have previously been
described in a COS protocol and are prespecified to re-
duce researcher bias [12]. The results of this process will
be brought forward to the consensus group meeting.
Consensus group meeting
Methods This final phase will involve a face-to-face
meeting with key stakeholders. The meeting participants
will be sampled purposively to ensure a range of views
of patients, clinicians and researchers with expertise in
diabetes care. The sample will be drawn from among
those who completed all rounds of the Delphi study.
The results obtained from each round of the Delphi sur-
vey will be presented. Review of the responses from
round 3 of the Delphi exercise will inform the structure
and content of the meeting. The objective of the consen-
sus meeting is to discuss outcomes about which there
was disagreement in round 3 of the Delphi study and to
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constitute the COS.
Participants
The consensus group will include, at a minimum, two rep-
resentatives from obstetrics, endocrinology, midwifery,
diabetes specialist nursing and dietetics; at least three ser-
vice users; and members of the SAG. A half-day meeting
is planned and to achieve effective consensus the facilita-
tor will ensure that the meeting is collaborative, coopera-
tive, egalitarian, inclusive and participatory.
Discussion
There is currently no COS for studies assessing the ef-
fectiveness of prepregnancy care for women with preges-
tational diabetes mellitus. The aim of development of
such a COS in this clinical area is to improve the inter-
pretation and comparison of future studies while redu-
cing the risk of outcome reporting bias. We will involve
key stakeholders and use recognised techniques to en-
sure that the ensuing COS is suitable and well accepted
in future research.
Trial status
The study plan is to complete the systematic review by
January 2016 and development of the core outcome set
by November 2016.Additional file
Additional file 1: Systematic review search strategies. This file
outlines the detailed search strategies and time limits applied to each of
the databases used in the systematic review. (DOCX 64 kb)
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